ALM 201

Drug Profile

ALM 201

Alternative Names: ALM-201; FKBPL; FKBPL-derived anticancer peptides; Peptide anti-angiogenic compounds - Queens University Belfast/Almac Discovery

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Almac Discovery; Queens University Belfast
  • Developer Almac Discovery
  • Class Antineoplastics; Peptide fragments
  • Mechanism of Action Angiogenesis inhibitors; CD44 antigen modulators; Cell movement inhibitors; Immunophilin modulators; Microtubule protein modulators; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Phase I Ovarian cancer; Solid tumours

Most Recent Events

  • 08 Sep 2017 Pharmacokinetics and adverse events data from a phase I trial in Solid tumours presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 03 Jul 2017 ALM 201 receives Orphan Drug status for Ovarian cancer in USA
  • 14 Feb 2017 Almac Discovery and RCSI enter into research collaboration for ALM 201 for the treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top